CA2358487A1 - Use of phanquinone for the treatment or prevention of memory impairment - Google Patents

Use of phanquinone for the treatment or prevention of memory impairment Download PDF

Info

Publication number
CA2358487A1
CA2358487A1 CA002358487A CA2358487A CA2358487A1 CA 2358487 A1 CA2358487 A1 CA 2358487A1 CA 002358487 A CA002358487 A CA 002358487A CA 2358487 A CA2358487 A CA 2358487A CA 2358487 A1 CA2358487 A1 CA 2358487A1
Authority
CA
Canada
Prior art keywords
phanquinone
prevention
treatment
memory impairment
suggested
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002358487A
Other languages
French (fr)
Other versions
CA2358487C (en
Inventor
Michel Xilinas
Panayotis Nikolas Gerolymatos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PN Gerolymatos SA
Original Assignee
PN Gerolymatos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PN Gerolymatos SA filed Critical PN Gerolymatos SA
Publication of CA2358487A1 publication Critical patent/CA2358487A1/en
Application granted granted Critical
Publication of CA2358487C publication Critical patent/CA2358487C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The use of phanquinone (4,7-phenanthroline-5,6-dione) for the treatment or prevention of memory impairment is suggested. Also a method for improving the learning or memory of a normal subject is suggested, said method comprising the administering of phanquinone, optionally together with one or more pharmaceutically acceptable carrier(s).
CA002358487A 1999-01-07 2000-01-06 Use of phanquinone for the treatment or prevention of memory impairment Expired - Fee Related CA2358487C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR99100005 1999-01-07
GR990100005 1999-01-07
PCT/IB2000/000011 WO2000040244A1 (en) 1999-01-07 2000-01-06 Use of phanquinone for the treatment or prevention of memory impairment

Publications (2)

Publication Number Publication Date
CA2358487A1 true CA2358487A1 (en) 2000-07-13
CA2358487C CA2358487C (en) 2008-11-18

Family

ID=10943706

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002358487A Expired - Fee Related CA2358487C (en) 1999-01-07 2000-01-06 Use of phanquinone for the treatment or prevention of memory impairment

Country Status (17)

Country Link
US (1) US7030136B2 (en)
EP (1) EP1140090B1 (en)
JP (1) JP2002534386A (en)
AR (1) AR022215A1 (en)
AT (1) ATE285235T1 (en)
AU (1) AU1792200A (en)
BR (1) BR0008241A (en)
CA (1) CA2358487C (en)
DE (1) DE60016892T2 (en)
DK (1) DK1140090T3 (en)
ES (1) ES2234559T3 (en)
HK (1) HK1042039B (en)
IL (1) IL143903A (en)
PT (1) PT1140090E (en)
SI (1) SI1140090T1 (en)
TR (1) TR200101892T2 (en)
WO (1) WO2000040244A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513558A (en) 1997-08-21 2001-09-04 パイ・ニュー・ゲロリュマトス・ソシエテ・アノニム How to use fanquinone to treat Alzheimer's disease
WO2001082912A2 (en) * 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
EP0275668B1 (en) * 1986-12-17 1992-09-30 Glaxo Group Limited Use of ketone derivatives in the treatment of cognitive disorders
US5091391A (en) 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
WO1993010459A1 (en) 1991-11-12 1993-05-27 The University Of Melbourne A method for assaying and treating alzheimer's disease
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
US5792774A (en) * 1996-02-21 1998-08-11 Chiroscience Limited Quinolones and their therapeutic use
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
CA2264097C (en) 1996-08-13 2007-11-27 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP1007048A4 (en) 1997-03-11 2004-09-22 Gen Hospital Corp Identification of agents for use in the treatment of alzheimer's disease
JP2001513558A (en) * 1997-08-21 2001-09-04 パイ・ニュー・ゲロリュマトス・ソシエテ・アノニム How to use fanquinone to treat Alzheimer's disease
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof

Also Published As

Publication number Publication date
US7030136B2 (en) 2006-04-18
PT1140090E (en) 2005-05-31
CA2358487C (en) 2008-11-18
BR0008241A (en) 2001-10-30
IL143903A (en) 2004-02-08
DE60016892D1 (en) 2005-01-27
WO2000040244A1 (en) 2000-07-13
EP1140090A1 (en) 2001-10-10
DK1140090T3 (en) 2005-04-18
ES2234559T3 (en) 2005-07-01
TR200101892T2 (en) 2001-11-21
AR022215A1 (en) 2002-09-04
SI1140090T1 (en) 2005-06-30
AU1792200A (en) 2000-07-24
IL143903A0 (en) 2002-04-21
HK1042039B (en) 2005-07-29
JP2002534386A (en) 2002-10-15
US20030055078A1 (en) 2003-03-20
ATE285235T1 (en) 2005-01-15
DE60016892T2 (en) 2005-12-15
HK1042039A1 (en) 2002-08-02
EP1140090B1 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
CA2263561A1 (en) Thienopyrimidines
EP2087892A3 (en) (S,S) reboxetine for treating age associated learning and mental disorders
AU5032500A (en) Treatment of irregular ventricular contractions
EP1106202A3 (en) Electrode for intravascular stimulation, cardioversion and /or defibrillation
CA2086974A1 (en) R(+)-terazosin
EP1574219A3 (en) Method of inhibiting fibrosis with a somatostatin agonist
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
HK1048306A1 (en) Pharmaceutically active sulfonamide derivatives.
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
CA2294921A1 (en) Levobupivacaine and its use
CA2328280A1 (en) Thienopyrimidines
EP1440691A3 (en) Treatment of neurotic disorders
AU1614097A (en) Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts
HK1022432A1 (en) Administration of histamine for therapeutic purposes.
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
WO2000010554A3 (en) Methods and compositions employing optically pure s(+) vigabatrin
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
CA2358487A1 (en) Use of phanquinone for the treatment or prevention of memory impairment
JO2181B1 (en) Prucalopride oral solution
WO1998022099A3 (en) New use of creatine
CY2388B1 (en) Rate-controlled transdermal administration of risperidone.
ZA200006081B (en) Novel octahydro-6, 10-dioxo-6h-pyridazino/1,2-A/ /1,2/diazepin-1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds.
ZA200107523B (en) Method for improving the stability of stored and/or light-sensitive therapeutic systems or component thereof.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed